Recent evidence is growing that common antidepressants may help reduce the severity and mortality of COVID-19. People taking selective serotonin reuptake inhibitors (or RSSIs) were found to be 8%-26% less likely to die from COVID.
While new antivirals are being developed, one of the benefits of these RSSIs is that they have been in use for some time and their side effects are already well known.
Further research is needed to confirm the effectiveness of RSSIs on varying stages of COVID-19 patients. Success would mean another weapon in our fight against the pandemic.